NASDAQ:PSTV - PlusTherapeuticsInc . Stock Price, News & Analysis

-1.35 (-14.52 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
Now: $7.95
50-Day Range N/A
52-Week Range
Now: $7.95
Volume188,146 shs
Average Volume154,223 shs
Market Capitalization$3.60 million
P/E RatioN/A
Dividend YieldN/A
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi's sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:PSTV



Sales & Book Value

Annual Sales$3.67 million
Book Value$17.62 per share


Net Income$-12,630,000.00
Net Margins-492.45%


Market Cap$3.60 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive PSTV News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.

PlusTherapeuticsInc . (NASDAQ:PSTV) Frequently Asked Questions

What is PlusTherapeuticsInc .'s stock symbol?

PlusTherapeuticsInc . trades on the NASDAQ under the ticker symbol "PSTV."

How were PlusTherapeuticsInc .'s earnings last quarter?

PlusTherapeuticsInc . (NASDAQ:PSTV) announced its quarterly earnings data on Thursday, August, 15th. The company reported ($5.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($9.75) by $4.63. The firm earned $0.30 million during the quarter. PlusTherapeuticsInc . had a negative net margin of 492.45% and a negative return on equity of 546.87%. View PlusTherapeuticsInc .'s Earnings History.

When is PlusTherapeuticsInc .'s next earnings date?

PlusTherapeuticsInc . is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for PlusTherapeuticsInc ..

Has PlusTherapeuticsInc . been receiving favorable news coverage?

News stories about PSTV stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PlusTherapeuticsInc . earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for PlusTherapeuticsInc ..

Who are some of PlusTherapeuticsInc .'s key competitors?

What other stocks do shareholders of PlusTherapeuticsInc . own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PlusTherapeuticsInc . investors own include Bio-Path (BPTH), Aerie Pharmaceuticals (AERI), Ocular Therapeutix (OCUL), Athersys (ATHX), Amarin (AMRN), Advanced Micro Devices (AMD), Align Technology (ALGN), Akari Therapeutics (AKTX), Agile Therapeutics (AGRX) and AEterna Zentaris (AEZS).

Who are PlusTherapeuticsInc .'s key executives?

PlusTherapeuticsInc .'s management team includes the folowing people:
  • Dr. Marc H. Hedrick, CEO, Pres & Director (Age 56)
  • Mr. Alan Lins, Principal Financial & Accounting Officer, VP of Fin. and Controller
  • Dr. John K. Fraser Ph.D., Chief Scientist (Age 58)
  • Mr. Russ Havranek, VP of Global Marketing
  • Mr. Gary S. Titus, Advisor (Age 59)

How do I buy shares of PlusTherapeuticsInc .?

Shares of PSTV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PlusTherapeuticsInc .'s stock price today?

One share of PSTV stock can currently be purchased for approximately $7.95.

How big of a company is PlusTherapeuticsInc .?

PlusTherapeuticsInc . has a market capitalization of $3.60 million and generates $3.67 million in revenue each year. PlusTherapeuticsInc . employs 37 workers across the globe.View Additional Information About PlusTherapeuticsInc ..

What is PlusTherapeuticsInc .'s official website?

The official website for PlusTherapeuticsInc . is

How can I contact PlusTherapeuticsInc .?

PlusTherapeuticsInc .'s mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The company can be reached via phone at 737-255-7194 or via email at [email protected]

MarketBeat Community Rating for PlusTherapeuticsInc . (NASDAQ PSTV)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  20 (Vote Underperform)
Total Votes:  32
MarketBeat's community ratings are surveys of what our community members think about PlusTherapeuticsInc . and other stocks. Vote "Outperform" if you believe PSTV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel